<DOC>
	<DOCNO>NCT01597622</DOCNO>
	<brief_summary>This study provide subject complete BEL113750 study subject complete open-label extension HGS1006-C1115 ( refer C1115 ) Study Japan option continue treatment belimumab ( 10 mg/kg intravenously every 4 week ) randomize belimumab , option begin treatment belimumab randomize placebo , add-on standard care SLE therapy .</brief_summary>
	<brief_title>BEL114333 , Continuation Study BEL113750 Subjects With Systemic Lupus Erythematosus ( SLE ) Northeast Asia , Japan Subjects Completing Open-label Extension HGS1006-C1115</brief_title>
	<detailed_description>This multicentre , continuation study belimumab plus standard care ( SOC ) SLE subject complete Phase III BEL113750 protocol Northeast Asia complete open-label extension HGS1006-C1115 protocol Japan . This study provide subject complete BEL113750 study option continue treatment belimumab ( 10 mg/kg intravenously every 4 week ) randomize belimumab , option begin treatment belimumab randomize placebo , add-on SOC SLE therapy . Subjects participate continuation protocol continue monitor safety efficacy , measure SLE responder index . Subjects complete 48 week treatment BEL113750 study meet inclusion/exclusion criterion , provide inform consent , give option enter continuation study . All subject receive belimumab 10 mg/kg IV infuse 1 hour every 4 week . Subjects recruit study continue receive treatment belimumab time belimumab becomes commercially available subject 's country participation , subject elect participate another belimumab continuation study SLE , either subject 's physician withdraws subject study , upon decision sponsor discontinue development belimumab SLE .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Have complete BEL113750 Protocol Northeast Asia Week 48 OR complete openlabel extension C1115 Japan . Be able receive first dose belimumab BEL114333 four week ( minimum 2 week , maximum 8 week ) last dose BEL113750 OR able receive first dose IV belimumab 1 week ( plus 1 week visit window ) last dose openlabel SC belimumab C1115.. Have develop clinical evidence significant , unstable uncontrolled , acute chronic disease due SLE ( i.e. , cardiovascular , pulmonary , hematologic , gastrointestinal , hepatic , renal , neurological , malignancy infectious disease ) , experienced adverse event ( AE ) Phase 3 study could , opinion principal investigator , put subject undue risk . Have develop medical disease ( e.g. , cardiopulmonary ) , laboratory abnormality , condition ( e.g. , poor venous access ) opinion principal investigator , make subject unstable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SELENA</keyword>
	<keyword>belimumab</keyword>
	<keyword>Lupus</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>PGA</keyword>
	<keyword>BLys</keyword>
	<keyword>SLE Flare Index</keyword>
	<keyword>continuation</keyword>
	<keyword>phase III</keyword>
	<keyword>BILAG</keyword>
	<keyword>extension</keyword>
	<keyword>efficacy</keyword>
	<keyword>SRI</keyword>
	<keyword>B cell</keyword>
	<keyword>SLEDAI</keyword>
	<keyword>safety</keyword>
	<keyword>Asia</keyword>
	<keyword>B lymphocyte</keyword>
</DOC>